News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pluristem Therapeutics (PSTI)' CEO Quarterly Update



2/29/2012 9:44:43 AM

HAIFA, Israel, Feb. 29, 2012 (GLOBE NEWSWIRE) -- Dear Shareholders,

We at Pluristem have been very busy during the last few quarters in exploiting our unique competitive position in being the only company with the ability to manufacture mass quantities of cells in a three dimensional manner. This advantage has attracted the attention of pharmaceutical companies in supporting our out-license business model for our PLacental eXpanded (PLX) cells. We have made significant progress in our clinical trials' schedule in the area of peripheral artery disease (PAD) and muscle injury as well as expanded our PLX product pipeline by enhancing our activity in the area of radiation exposure. Additionally, we are on track with the build out of our new commercial grade manufacturing facility in Haifa and have substantially strengthened our management team.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES